

Edgar Filing: INTEGRA LIFESCIENCES HOLDINGS CORP - Form 8-K

INTEGRA LIFESCIENCES HOLDINGS CORP

Form 8-K

June 06, 2008

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2008

INTEGRA LIFESCIENCES HOLDINGS CORPORATION  
(Exact Name of Registrant as Specified in its Charter)

Delaware	0-26224	51-0317849
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

311 Enterprise Drive  
Plainsboro, NJ 08536  
(Address of Principal Executive Offices)  
(Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

Edgar Filing: INTEGRA LIFESCIENCES HOLDINGS CORP - Form 8-K

(e)

SPECIAL STOCK OPTION GRANT FOR CHIEF FINANCIAL OFFICER

On June 2, 2008, the Compensation Committee of the Board of Directors approved a stock option grant, effective as of July 1, 2008, to John B. Henneman, III, the Company's Executive Vice President, Finance and Administration, and Chief Financial Officer, in connection with his previously-announced appointment as Chief Financial Officer of the Company. The stock option grant will represent the right to acquire 50,000 shares of common stock at a per share exercise price equal to the fair market value on the date of grant. The grant will have a ten-year term and will vest with respect to 1/4 of the shares on December 31, 2008 and thereafter with respect to 1/36 of the remaining shares on the first business day of each following month.

A copy of the form of stock option agreement, approved by the Compensation Committee for use in connection with this grant, is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference into this Item.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

10.1 Form of stock option agreement for John B. Henneman, III

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: June 6, 2008

By: /s/ Stuart M. Essig

-----  
Stuart M. Essig

President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
-----	-----
10.1	Form of stock option agreement for John B. Henneman, III

